Table 2.
Phenotype Frequencies of HLA-A Alleles in Alabama Subjects.1
| A* Phenotypes | Frequency in CVID and IgGSD Index Patients (n= 240) | Frequency in Control Subjects (n) | Significant Uncorrected Values of p | Significant Corrected Values of p2 |
| 01 | 0.3458 | 0.3397 (1,319) | ||
| 02 | 0.5292 | 0.5206 (1,310) | ||
| 03 | 0.2875 | 0.2739 (1,318) | ||
| 11 | 0.075 | 0.1136 (1,320) | ||
| 23 | 0.0500 | 0.0375 (1,254) | ||
| 24 | 0.300 | 0.1304 (1,265) | < 0.0001 | < 0.0016 |
| 25 | 0.0333 | 0.0297 (1,281) | ||
| 26 | 0.0500 | 0.0634 (1,278) | ||
| 28 | 0.025 | 0.0773 (1,320) | ||
| 29 | 0.0583 | 0.0620 (1,290) | ||
| 30 | 0.0292 | 0.0405 (1,308) | ||
| 31 | 0.0542 | 0.0350 (1,258) | ||
| 32 | 0.0375 | 0.0536 (1,232) | ||
| 33 | 0.0083 | 0.0176 (1,248) | ||
| 34 | 0.0083 | 0.0044 (1,146) | ||
| 66 | 0.0167 | 0 (243) |
1 Phenotypes were detected using low-resolution DNA-based typing in CVID and IgGSD index patients and microlymphocytotoxcity typing in control subjects. Because our HLA typing was conducted over a period of several years during which splits of certain alleles had not been defined, we collapsed the phenotype HLA-A*10 into HLA-A*26 and the phenotype HLA-A*68 into HLA-A*28 to facilitate the present comparisons. 2These values were corrected using the Bonferroni inequality method.